Antisense permeation enhancers

Details Antisense permeation enhancers Antisense permeation enhancers

2006-08-23

2011-10-18

Jiang, Shaojia Anna (Department: 1623)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C514S558000, C536S025200

Reexamination Certificate

active

08039444

ABSTRACT:
A pharmaceutical composition comprising an antisense oligonucleotide and a permeation enhancer that comprises a multi-carbon backbone having a functional group and also one or more side chains which have one or more carbon atoms and, optionally, one or more functional groups.

REFERENCES:
patent: 4469671 (1984-09-01), Zimmerman et al.
patent: 4525339 (1985-06-01), Behl et al.
patent: 4645502 (1987-02-01), Gale et al.
patent: 4656161 (1987-04-01), Herr
patent: 4692452 (1987-09-01), Cerny et al.
patent: 4789547 (1988-12-01), Song et al.
patent: 4906463 (1990-03-01), Cleary et al.
patent: 4910205 (1990-03-01), Kogan et al.
patent: 4911916 (1990-03-01), Cleary
patent: 4994273 (1991-02-01), Zentner et al.
patent: 5087620 (1992-02-01), Parab
patent: 5091171 (1992-02-01), Yu et al.
patent: 5190748 (1993-03-01), Bachynsky et al.
patent: 5229130 (1993-07-01), Sharma et al.
patent: 5288497 (1994-02-01), Stanley et al.
patent: 5374633 (1994-12-01), Parab
patent: 5399355 (1995-03-01), Riedl et al.
patent: 5492698 (1996-02-01), Von Kleinsorgen
patent: 5541155 (1996-07-01), Leone-Bay et al.
patent: 5580574 (1996-12-01), Behl et al.
patent: 5650386 (1997-07-01), Leone-Bay et al.
patent: 5662926 (1997-09-01), Wick et al.
patent: 5714477 (1998-02-01), Einarsson
patent: 5801154 (1998-09-01), Baracchini et al.
patent: 5834010 (1998-11-01), Quan et al.
patent: 5837289 (1998-11-01), Grasela et al.
patent: 5854281 (1998-12-01), Uekama et al.
patent: 5863555 (1999-01-01), Heiber et al.
patent: 5866157 (1999-02-01), Higo et al.
patent: 5912009 (1999-06-01), Venkateshwaran et al.
patent: 5952000 (1999-09-01), Venkateshwaran et al.
patent: 5977175 (1999-11-01), Lin
patent: 6001390 (1999-12-01), Yum et al.
patent: 6010716 (2000-01-01), Saunal et al.
patent: 6051609 (2000-04-01), Yu et al.
patent: 6132760 (2000-10-01), Hedenstrom et al.
patent: 6153209 (2000-11-01), Vega et al.
patent: 6200602 (2001-03-01), Watts et al.
patent: 6203817 (2001-03-01), Cormier et al.
patent: 6262161 (2001-07-01), Kawaji et al.
patent: 6264981 (2001-07-01), Zhang et al.
patent: 6267985 (2001-07-01), Chen et al.
patent: 6268355 (2001-07-01), Mizobuchi et al.
patent: 6326360 (2001-12-01), Kanazawa et al.
patent: 6379960 (2002-04-01), Popoff
patent: 6582908 (2003-06-01), Fodor et al.
patent: 2001/0053519 (2001-12-01), Fodor et al.
patent: 2003/0018085 (2003-01-01), Raoof et al.
patent: 2003/0228597 (2003-12-01), Cowsert et al.
patent: 2007/0031844 (2007-02-01), Khvorova et al.
patent: 0 370 481 (1990-05-01), None
patent: 0 376 534 (1990-07-01), None
patent: 0 497 162 (1992-08-01), None
patent: 0 517 211 (1992-12-01), None
patent: 0 580 074 (1994-01-01), None
patent: 953 626 (1964-03-01), None
patent: 51 031687 (1976-03-01), None
patent: 2-207018 (1990-08-01), None
patent: 02-207018 (1990-08-01), None
patent: 2-282327 (1990-11-01), None
patent: 6-40949 (1994-02-01), None
patent: 11-35458 (1999-02-01), None
patent: WO 84/04674 (1984-12-01), None
patent: WO 93/21907 (1993-11-01), None
patent: WO 95/22319 (1995-08-01), None
patent: WO 95/34294 (1995-12-01), None
patent: WO 97/05903 (1997-02-01), None
patent: WO 99/01579 (1999-01-01), None
patent: WO 99/02120 (1999-01-01), None
patent: WO 99/02485 (1999-01-01), None
patent: WO 99/45934 (1999-09-01), None
patent: WO 99/60012 (1999-11-01), None
patent: WO 00/22909 (2000-04-01), None
patent: WO 00/50012 (2000-08-01), None
patent: WO 02/092070 (2002-11-01), None
Muranishi, Critical Reviews in Therapeutic Drug Carrier Systems, 1990, 7(1), 1-33.
Branch et al., “A good antisense molecule is hard to find,” TIBS (1998) 23:45-50.
Chin, Andrew “On the Preparation and Utilization of Isolated and Purified Oligonucleotides.” Document purportedly located on a CD-ROM and contributed to the public collection of the Katherine R. Everett Law Library of the University of North Carolina on Mar. 14, 2002.
Crooke et al., “Basic Principles of Antisense Therapeutics” Antisense Research and Application (1998) Chapter 1:1-50.
Cumming et al., “In vitro evaluation of a series of sodium carboxylates as dermal penetration enhancers” International Journal of Pharmaceuticals (1994) 108(2):141-148.
International Search Report from PCT/US2002/015166, dated Sep. 19, 2002.
New England BioLabs, Inc. Catalogue (1998): 121, 284.
Reynolds et al., Rational siRNA design for RNA interference, Mar. 2004, Nature Biotechnology, vol. 22, pp. 326-330.
Sanghvi et al., “Heterocyclic Base Modifications in Nucleic Acids and Their Applications in Antisense Oligonucleotides” Antisense Research and Applications (1993) pp. 273-288.
Supplementary European Search Report for Application EP 02731781 dated Jun. 6, 2008.
Anderberg et al., “Sodium Caprate Elicits Dilatations in Human Intestinal Tight Junctions and Enhances Drug Absorption by the Paracellular Route”, Pharmaceutical Research (1993), 10:857-864.
Artursson, P., “Epithelial Transport of Drugs in Cell Culture. I: A model for Studying the Passive Diffusion of Drugs over Intestinal Absorbative (Caco-2) Cells”, J. Pharmaceutical Studies (1990), 79: 476-482.
Aungst, “Structure/Effect Studies of Fatty Acid Isomers as Skin Penetration Enhancers and Skin Irritants” Phamaceutical Research 6(3):244-247 (1989).
Aungst, et al., “Enhancement of the Intestinal Absorption of Peptides and Non-peptides”, J. of Controlled Release (1996), 41:19-31.
Bennett et al, “Pulmonary Delivery of Detirelix Intratracheal Instillation and Aerosol Inhalation in the Briefly Anesthetized Dog”, Pharmaceutical Research (1994), vol. 11, No. 7, 1048-1054.
Brayden et al,“Heparin Absorption Across the Intestine: Effects of Sodium N-[8-(2-Hydroxybenzoyl)Amino]Caprylate in Rat in Situ Intestinal Instillations and in Caco-2 Monolayers”, Pharmaceutical Research, 1997, 14(12), 1772-1779.
Doluisio et al, “Drug Absorption I: An in Situ Rat Gut Technique Yielding Realistic Absorption Rates”, J. Pharmaceutical Studies (1969), 59:1196-1200.
Gennaro, A.R., Remingtion: The Science and Practice of Pharmacy (1995), 1618.
Lee et al, “Critical Reviews in Therapeutic Drug Carrier Systems”, 1991, 8(2), 91-192.
Lindmark et al., “Mechanism of Absorption Enhancement in Humans After Rectal Administration of Ampicillin in Suppositories Containing Sodium Caprate”, Pharmaceutical Research (1997), 14:930-935.
Oda et al, Proc. Int'l Symp. Control. Rel. Bioact. Mater. 24 (1997) 283-284.
Schneider et al. “Evaluation of Drug Penetration into Human Skin Ex Vivo Using Branched Fatty Acids and Propylene Glycol”International Journal of Pharmaceutics145:187-196 (1996).
Tomita et al., “Enhancement of Colonic Drug Absorption by the Paracellular Permeation Route”, Pharmaceutical Research (1988), 5:341-346.
Yeh et al,Effect of Medium-chain Glycerides on Physiological Properties of Rabbit Intestinal Epithelium in Vitro, Pharmaceutical Research (1994), 11:1148-1154.
English translation of abstract of Japanese Patent Application No. JP 03 275 633, filed Dec. 6, 1991.
English translation of abstract of Japanese Patent Application No. JP 2004529953, filed Sep. 30, 2004.
English translation of abstract of Japanese Patent Application No. JP 59 073 600, filed Apr. 25, 1984.
English translation of abstract of Russian Patent Application No. RU 2 068 689, filed Nov. 10, 1996.

Affiliated with

Also associated with

Rating

Antisense permeation enhancers does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antisense permeation enhancers, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antisense permeation enhancers will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4290216